Article
Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial.
ESMO open - 1 Mar 2024
Tabernero J, Taieb J, Fakih M, Prager G W, Van Cutsem E, Ciardiello F, Mayer R J, Amellal N, Skanji D, Calleja E, Yoshino T
Abstract excerpt
BACKGROUND: In metastatic colorectal cancer (mCRC), KRAS mutations are often associated with poorer survival; however, the prognostic impact of specific point mutations is unclear. In the phase III SUNLIGHT trial, trifluridine/tipiracil (FTD/TPI) plus bevacizumab significantly improved overall survival (OS) versus FTD/TPI alone. We assessed the impact of KRASG12 mutational status on OS in SUNLIGHT. PATIENTS AND...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.